Southern Research Institute;The UAB Research Foundation
发明人:
申请号：
EP14794379.9
公开号：
EP2994156A4
申请日:
2014.05.09
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting the activity of the transforming growth factor beta (TGF-&bgr；). More specifically, the disclosed compounds, compositions and methods are useful in the treatment of certain cancers (e.g. multiple myeloma, hematologic malignancies), diseases associated with excessive TGF-&bgr； activity including fibrosis, dermal scarring, immune dysfunction, and bone loss by inhibiting the conversion of latent TGF-&bgr； to active TGF-&bgr；. A method of preventing the activation of TGF-&bgr； in pathology is also provided, comprising administering an amount of the compounds sufficient to inhibit conversion of latent TGF-&bgr； to active TGF-&bgr； by thrombospondin1 (TSP1), resulting in reduced TGF-&bgr； activity and reduced adverse effects such as fibrosis, bone loss, and immune dysfunction.
